Pradžia › Rabdomiosarkoma
Rabdomiosarkoma klinikiniai tyrimai JAV ieško dalyvių
26 tyrimai dėl Rabdomiosarkoma ieško dalyvių vietose visoje Jungtinėse Valstijose.
Miestai su daugiausia tyrimų
- Houston, TX6 tyrimai
- Memphis, TN6 tyrimai
- Washington, DC5 tyrimai
- Philadelphia, PA4 tyrimai
- Boston, MA4 tyrimai
- Salt Lake City, UT4 tyrimai
- Seattle, WA3 tyrimai
- Aurora, CO3 tyrimai
- Dallas, TX3 tyrimai
- Birmingham, AL3 tyrimai
- The Bronx, NY3 tyrimai
- Baltimore, MD3 tyrimai
Pagal valstiją
- Alabama3 tyrimai
- Florida3 tyrimai
- Kalifornija7 tyrimai
- Koloradas3 tyrimai
- Kolumbijos apskritis4 tyrimai
- Masčusetsas4 tyrimai
- Merilendas4 tyrimai
- New York4 tyrimai
- Ohio5 tyrimai
- Pennsylvania5 tyrimai
- Tennessee8 tyrimai
- Texas9 tyrimai
- Utah4 tyrimai
- Washington3 tyrimai
Nesenai atnaujinti tyrimai
Oficialus tyrimo tekstas (anglų kalba)
FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma
Renkami dalyviai1 fazė
Amžius nuo 3 iki 39 · Visoms lytims · Atnaujinta 2026-09-29 · NCT06865664Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
Renkami dalyviai1 fazė
24 Months – 18 Years · Visoms lytims · Atnaujinta 2026-09-25 · NCT06441331Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
Renkami dalyviai1/2 fazė
Iki 30 metų · Visoms lytims · Atnaujinta 2026-09-03 · NCT06541262A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Renkami dalyviai3 fazė
Iki 50 metų · Visoms lytims · Atnaujinta 2026-08-25 · NCT07466316Integration of Adaptive Proton Therapy in Pediatric Solid Tumors and Hodgkin's Lymphoma
Renkami dalyviai
Visi amžiai · Visoms lytims · Atnaujinta 2026-08-21 · NCT07514819Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)
Renkami dalyviai1 fazė
Amžius nuo 1 iki 23 · Visoms lytims · Atnaujinta 2026-08-13 · NCT07172958Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-06 · NCT05210374Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors
Renkami dalyviai1 fazė
Amžius nuo 1 iki 21 · Visoms lytims · Atnaujinta 2026-08-06 · NCT04715191Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/ Solid Tumors
Renkami dalyviaiAnkstyvoji 1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-31 · NCT07628634PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Renkami dalyviai1/2 fazė
Amžius nuo 1 iki 30 · Visoms lytims · Atnaujinta 2026-07-22 · NCT06721689Targeted Oligometastatic Radiation in Pediatric and Young Adult Patients With Soft Tissue and Bone Sarcoma
Renkami dalyviai
Iki 39 metų · Visoms lytims · Atnaujinta 2026-07-13 · NCT06796543Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Renkami dalyviai1/2 fazė
6 Months – 25 Years · Visoms lytims · Atnaujinta 2026-06-30 · NCT06625190Familial Investigations of Childhood Cancer Predisposition
Renkami dalyviaiStebimasis tyrimas
Visi amžiai · Visoms lytims · Atnaujinta 2026-06-17 · NCT03050268Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
Renkami dalyviai2 fazė
Iki 22 metų · Visoms lytims · Atnaujinta 2026-06-15 · NCT06023641VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
Renkami dalyviai1/2 fazė
6 Months – 30 Years · Visoms lytims · Atnaujinta 2026-06-02 · NCT04796012B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
Renkami dalyviai1 fazė
Iki 21 metų · Visoms lytims · Atnaujinta 2026-05-19 · NCT04897321Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Renkami dalyviai1/2 fazė
12 Months – 30 Years · Visoms lytims · Atnaujinta 2026-05-19 · NCT04901702Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
Renkami dalyviai1 fazė
Amžius nuo 1 iki 30 · Visoms lytims · Atnaujinta 2026-04-15 · NCT04308330Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Renkami dalyviai2 fazė
Amžius nuo 1 iki 50 · Visoms lytims · Atnaujinta 2026-03-13 · NCT01804634Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Renkami dalyviai1/2 fazė
Amžius nuo 12 iki 49 · Visoms lytims · Atnaujinta 2026-02-19 · NCT06709495Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells
Renkami dalyviai1 fazė
Amžius nuo 1 iki 26 · Visoms lytims · Atnaujinta 2026-02-17 · NCT07148050HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma
Renkami dalyviai1 fazė
Amžius nuo 1 iki 25 · Visoms lytims · Atnaujinta 2026-01-22 · NCT04995003Molecular Analysis Of Solid Tumors
Renkami dalyviaiStebimasis tyrimas
Iki 25 metų · Visoms lytims · Atnaujinta 2025-11-12 · NCT01050296Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
Renkami dalyviai1 fazė
Iki 21 metų · Visoms lytims · Atnaujinta 2025-11-03 · NCT06198296Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
Renkami dalyviai1 fazė
7 Months – 21 Years · Visoms lytims · Atnaujinta 2025-10-16 · NCT02508038Iš ClinicalTrials.gov, duomenys gauti 2026-10-04. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.